---
title: "SNSW issued a profit warning, expecting a year-on-year increase of 253.54% in net profit attributable to the parent company for the first half of the year, reaching 332.1 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/245250157.md"
description: "SNSW expects that the net profit attributable to the parent company in the first half of 2025 will increase by 253.54% to 332.10% year-on-year, with an estimated net profit of RMB 77.0275 million to RMB 94.1448 million. After deducting non-recurring gains and losses, the net profit is expected to be RMB 77.3464 million to RMB 94.5345 million, an increase of 304.49% to 394.38% year-on-year. The company's peptide raw material drug business has performed well, significantly boosting its performance"
datetime: "2025-06-19T09:21:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/245250157.md)
  - [en](https://longbridge.com/en/news/245250157.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/245250157.md)
---

# SNSW issued a profit warning, expecting a year-on-year increase of 253.54% in net profit attributable to the parent company for the first half of the year, reaching 332.1 million

According to the Zhitong Finance APP, SNSW (688117.SH) disclosed its performance forecast for the first half of 2025. The company expects to achieve a net profit attributable to the owners of the parent company of between 77.0275 million yuan and 94.1448 million yuan for the first half of 2025, representing a year-on-year increase of 253.54% to 332.10%. It is expected that the net profit attributable to the owners of the parent company, after deducting non-recurring gains and losses, will be between 77.3464 million yuan and 94.5345 million yuan, representing a year-on-year increase of 304.49% to 394.38%.

In the first half of 2025, the company's peptide raw material drug business performed well, resulting in significant year-on-year growth in performance and a notable increase in net profit

### Related Stocks

- [688117.CN](https://longbridge.com/en/quote/688117.CN.md)

## Related News & Research

- [US Senator Durbin urges RFK. Jr to resist easing vape rules](https://longbridge.com/en/news/287079463.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [07:02 ETUSD Breaks Ground on New Shiley STEM Initiative Building, Transforming USD's STEM Education and Research](https://longbridge.com/en/news/287052919.md)
- [ZAWYA: Etihad Airways makes Eid al-Adha and summer travel easier with rewards, extra baggage and smart check-in options](https://longbridge.com/en/news/287036535.md)
- [AlzeCure Pharma to Host Live Seminar on The Pain Project TrkA-NAM ACD137 with a Focus on Osteoarthritis and Neuropathic Pain](https://longbridge.com/en/news/286879044.md)